<Summary id="CDR0000062979"><SummaryMetaData><SummaryType>Integrative, alternative, and complementary therapies</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Coenzyme Q10 is a dietary supplement, and use of it as a treatment for cancer in humans has been investigated in only a limited manner. Get detailed information about Coenzyme Q10 use in cancer in this summary for clinicians.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq">Coenzyme Q10 (PDQ®)</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/about-cancer/treatment/cam/patient/coenzyme-q10-pdq">Coenzyme Q10 (PDQ®)</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000256158">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000039187">coenzyme Q10</TermRef></MainTopics><SummaryAbstract><Para id="_62">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of coenzyme Q10 in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_63">This summary is reviewed regularly and updated as necessary by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>coenzyme Q10</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Coenzyme Q10 (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Coenzyme Q10 (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Coenzyme Q10</AltTitle><SummarySection id="_1"><Title>Overview</Title><Para id="_2">This <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> information summary provides an overview of
the use of <GlossaryTermRef href="CDR0000346488" dictionary="Cancer.gov" audience="Patient">coenzyme</GlossaryTermRef> Q<Subscript>10</Subscript> in cancer therapy.  The summary includes a
history of coenzyme Q<Subscript>10</Subscript> research, a review of <GlossaryTermRef href="CDR0000044512" dictionary="Cancer.gov" audience="Patient">laboratory studies</GlossaryTermRef>,
and data from investigations involving human subjects.  Although several
naturally occurring forms of coenzyme Q have been identified, Q<Subscript>10</Subscript>
is the predominant form found in humans and most mammals, and it is the form
most studied for <GlossaryTermRef href="CDR0000043985" dictionary="Cancer.gov" audience="Patient">therapeutic</GlossaryTermRef> 
potential.  Thus, it will be the only form of coenzyme Q discussed in this
summary.  </Para><Para id="_3">This summary contains the following key information:</Para><ItemizedList id="_4" Style="bullet">
         <ListItem>Coenzyme Q<Subscript>10</Subscript> is made naturally by the human body.</ListItem>
         <ListItem>Coenzyme Q<Subscript>10</Subscript> helps <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> to produce energy, and it acts as an 
<GlossaryTermRef href="CDR0000043997" dictionary="Cancer.gov" audience="Patient">antioxidant</GlossaryTermRef>.</ListItem>
         <ListItem>Coenzyme Q<Subscript>10</Subscript> has shown an ability to stimulate the <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune
system</GlossaryTermRef> and to protect the heart from damage caused by certain
 <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> drugs.</ListItem>
         <ListItem>Low <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> levels of coenzyme Q<Subscript>10</Subscript> have been detected in
patients with some types of cancer.</ListItem>
         <ListItem>No report of a <GlossaryTermRef href="CDR0000045858" dictionary="Cancer.gov" audience="Patient">randomized clinical trial</GlossaryTermRef> 
of coenzyme Q<Subscript>10</Subscript> as a treatment for cancer has been published in a
peer-reviewed scientific journal.</ListItem>
         <ListItem>Coenzyme Q<Subscript>10</Subscript> is marketed in the United States as a <GlossaryTermRef href="CDR0000373932" dictionary="Cancer.gov" audience="Patient">dietary
supplement</GlossaryTermRef>.</ListItem>
        </ItemizedList><Para id="_34">Many of the medical and scientific terms used in the summary are hypertext linked (at first use in each section) to the <ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary  of Cancer Terms</ExternalRef>, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window.</Para><Para id="_35">Reference citations in some <GlossaryTermRef href="CDR0000044271" dictionary="Cancer.gov" audience="Patient">PDQ</GlossaryTermRef> cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_5"><Title>General Information</Title><Para id="_6"><GlossaryTermRef href="CDR0000346488" dictionary="Cancer.gov" audience="Patient">Coenzyme</GlossaryTermRef> Q<Subscript>10</Subscript> (also known as CoQ<Subscript>10</Subscript>, Q<Subscript>10</Subscript>,
vitamin Q<Subscript>10</Subscript>, ubiquinone, and ubidecarenone) is a benzoquinone
compound synthesized naturally by the human body.  The “Q” and the “10” in the
name refer to the quinone chemical group and the 10 isoprenyl subunits that are part of this compound’s structure.  The term 
“coenzyme” denotes it as an organic (contains carbon atoms), nonprotein <GlossaryTermRef href="CDR0000045065" dictionary="Cancer.gov" audience="Patient">molecule</GlossaryTermRef> necessary for the proper
functioning of its <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> partner (an <GlossaryTermRef href="CDR0000046081" dictionary="Cancer.gov" audience="Patient">enzyme</GlossaryTermRef> or an enzyme complex).  Coenzyme
Q<Subscript>10</Subscript> is used by <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> of the body in a process known variously as: </Para><ItemizedList id="_78" Style="bullet">
     <ListItem><GlossaryTermRef href="CDR0000043993" dictionary="Cancer.gov" audience="Patient">Aerobic respiration</GlossaryTermRef>.</ListItem><ListItem> <GlossaryTermRef href="CDR0000043992" dictionary="Cancer.gov" audience="Patient">Aerobic metabolism</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044071" dictionary="Cancer.gov" audience="Patient">Oxidative metabolism</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044008" dictionary="Cancer.gov" audience="Patient">Cell respiration</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_79">Through this
process, mitochondria produce energy for cell growth and maintenance.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> 
Coenzyme Q<Subscript>10</Subscript> is also used by the body as an <GlossaryTermRef href="CDR0000044026" dictionary="Cancer.gov" audience="Patient">endogenous</GlossaryTermRef> <GlossaryTermRef href="CDR0000043997" dictionary="Cancer.gov" audience="Patient">antioxidant</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/>  An antioxidant is a substance that protects cells from 
<GlossaryTermRef href="CDR0000044030" dictionary="Cancer.gov" audience="Patient">free radicals</GlossaryTermRef>, which are highly
reactive chemicals, often containing oxygen atoms, capable of damaging
important cellular components such as <GlossaryTermRef href="CDR0000044393" dictionary="Genetics" audience="Health professional">DNA</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046068" dictionary="Cancer.gov" audience="Patient">lipids</GlossaryTermRef>.  In addition, the <GlossaryTermRef href="CDR0000045839" dictionary="Cancer.gov" audience="Patient">plasma</GlossaryTermRef> level of coenzyme Q<Subscript>10</Subscript> has
been used in studies as a measure of <GlossaryTermRef href="CDR0000044072" dictionary="Cancer.gov" audience="Patient">oxidative stress</GlossaryTermRef>.<Reference refidx="9"/><Reference refidx="10"/></Para><Para id="_7">Coenzyme Q<Subscript>10</Subscript> is present in most <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef>, but the highest
concentrations are found in the following organs:<Reference refidx="11"/>  </Para><ItemizedList id="_80" Style="bullet"><ListItem> Heart.</ListItem><ListItem><GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">Liver</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046325" dictionary="Cancer.gov" audience="Patient">Kidneys</GlossaryTermRef>. </ListItem><ListItem><GlossaryTermRef href="CDR0000046254" dictionary="Cancer.gov" audience="Patient">Pancreas</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_81">The lowest concentration is
found in the <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lungs</GlossaryTermRef>.<Reference refidx="11"/>  Tissue levels of this compound decrease as people age,
due to increased requirements, decreased production,<Reference refidx="11"/> or insufficient intake
of the chemical precursors needed for synthesis.<Reference refidx="12"/>  In humans,
normal <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> levels of coenzyme Q<Subscript>10</Subscript> have been defined variably,
with reported normal values ranging from 0.30 to 3.84 <GlossaryTermRef href="CDR0000306521" dictionary="Cancer.gov" audience="Patient">µg</GlossaryTermRef>/<GlossaryTermRef href="CDR0000044214" dictionary="Cancer.gov" audience="Patient">mL</GlossaryTermRef>.<Reference refidx="2"/><Reference refidx="4"/><Reference refidx="13"/><Reference refidx="14"/></Para><Para id="_8">Given the importance of coenzyme Q<Subscript>10</Subscript> in optimizing cellular energy
production, use of this compound as a treatment for diseases other than <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> 
has been explored.  Most of these investigations have focused on coenzyme
Q<Subscript>10</Subscript> as a treatment for <GlossaryTermRef href="CDR0000044005" dictionary="Cancer.gov" audience="Patient">cardiovascular</GlossaryTermRef> disease.<Reference refidx="2"/><Reference refidx="4"/><Reference refidx="15"/>  In patients with cancer, coenzyme Q<Subscript>10</Subscript> has been shown to do the following:
</Para><ItemizedList id="_82" Style="bullet">
     <ListItem>Protect the heart from <GlossaryTermRef href="CDR0000044916" dictionary="Cancer.gov" audience="Patient">anthracycline</GlossaryTermRef>-induced 
<GlossaryTermRef href="CDR0000044004" dictionary="Cancer.gov" audience="Patient">cardiotoxicity</GlossaryTermRef> (anthracyclines are
a family of <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> drugs, including <GlossaryTermRef href="CDR0000560140" dictionary="Cancer.gov" audience="Patient">doxorubicin</GlossaryTermRef>, that have the potential to
damage the heart).<Reference refidx="3"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/></ListItem><ListItem> Stimulate the <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef>.<Reference refidx="19"/><Reference refidx="20"/></ListItem></ItemizedList><Para id="_83">  Stimulation of the immune system by this compound has also been observed
in <GlossaryTermRef href="CDR0000454774" dictionary="Cancer.gov" audience="Patient">animal studies</GlossaryTermRef> and in humans without cancer.<Reference refidx="21"/><Reference refidx="22"/><Reference refidx="23"/><Reference refidx="24"/><Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/>  In part because of its
 <GlossaryTermRef href="CDR0000285968" dictionary="Cancer.gov" audience="Patient">immunostimulatory</GlossaryTermRef> potential, coenzyme Q<Subscript>10</Subscript> has been used as an <GlossaryTermRef href="CDR0000045587" dictionary="Cancer.gov" audience="Patient">adjuvant therapy</GlossaryTermRef> in patients with
various types of cancer.<Reference refidx="17"/><Reference refidx="20"/><Reference refidx="28"/><Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/><Reference refidx="33"/></Para><Para id="_9">While coenzyme Q<Subscript>10</Subscript> may show indirect anticancer activity through
its effect(s) on the immune system, there is evidence to suggest that 
<GlossaryTermRef href="CDR0000044919" dictionary="Cancer.gov" audience="Patient">analogs</GlossaryTermRef> of this compound can suppress
cancer growth directly.  Analogs of coenzyme Q<Subscript>10</Subscript> have been shown to
inhibit the <GlossaryTermRef href="CDR0000044572" dictionary="Cancer.gov" audience="Patient">proliferation</GlossaryTermRef> of cancer cells <Emphasis><GlossaryTermRef href="CDR0000045733" dictionary="Cancer.gov" audience="Patient">in vitro</GlossaryTermRef></Emphasis> and the growth of cancer cells
 <GlossaryTermRef href="CDR0000046631" dictionary="Cancer.gov" audience="Patient">transplanted</GlossaryTermRef> into rats and mice.<Reference refidx="12"/><Reference refidx="34"/>  In view of these findings, it has
been proposed that analogs of coenzyme Q<Subscript>10</Subscript> may function as <GlossaryTermRef href="CDR0000045152" dictionary="Cancer.gov" audience="Patient">antimetabolites</GlossaryTermRef> to disrupt normal
 <GlossaryTermRef href="CDR0000044124" dictionary="Cancer.gov" audience="Patient">biochemical reactions</GlossaryTermRef> that are required for cell growth and/or survival and,
thus, that they may be useful as <GlossaryTermRef href="CDR0000044009" dictionary="Cancer.gov" audience="Patient">chemotherapeutic
agents</GlossaryTermRef>.<Reference refidx="12"/><Reference refidx="34"/></Para><Para id="_10">Several companies distribute coenzyme Q<Subscript>10</Subscript> as a <GlossaryTermRef href="CDR0000373932" dictionary="Cancer.gov" audience="Patient">dietary
supplement</GlossaryTermRef>.  In the United States, dietary supplements are regulated by the <GlossaryTermRef href="CDR0000454785" dictionary="Cancer.gov" audience="Patient">U.S. Food and Drug
Administration</GlossaryTermRef> (FDA) as a separate category from foods, cosmetics, and drugs. Unlike drugs, dietary supplements do not require premarket evaluation and approval by the FDA  unless specific disease <GlossaryTermRef href="CDR0000439419" dictionary="Cancer.gov" audience="Patient">prevention</GlossaryTermRef> or
treatment claims are made.  The quality and amount of ingredients in dietary supplements are also regulated by the FDA through Good Manufacturing Practices (GMPs). The FDA GMPs requires that every finished batch of dietary supplement meets each product specification for identity, purity, strength, composition, and limits on contamination that may <GlossaryTermRef href="CDR0000686042" dictionary="Cancer.gov" audience="Patient">adulterate</GlossaryTermRef> dietary supplements. Because dietary supplements are not formally
reviewed for manufacturing consistency every year, ingredients may vary considerably 
from lot to lot and there is no guarantee that ingredients claimed on product labels are present (or are present in the specified amounts).  The FDA has not approved coenzyme Q<Subscript>10</Subscript> for the treatment of cancer or any other medical condition.</Para><Para id="_11">To conduct <GlossaryTermRef href="CDR0000044168" dictionary="Cancer.gov" audience="Patient">clinical</GlossaryTermRef> drug research in the United States, researchers must
file an Investigational New Drug (IND) application with the FDA. The IND
application process is highly confidential, and IND information can be
disclosed only by the applicants.  No investigators have announced
that they have applied for an IND to study coenzyme Q<Subscript>10</Subscript> as a
treatment for cancer.</Para><Para id="_12">In animal studies, coenzyme Q<Subscript>10</Subscript> has been administered by
 <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injection</GlossaryTermRef> (<GlossaryTermRef href="CDR0000046682" dictionary="Cancer.gov" audience="Patient">intravenous</GlossaryTermRef>, 
<GlossaryTermRef href="CDR0000046339" dictionary="Cancer.gov" audience="Patient">intraperitoneal</GlossaryTermRef>, 
<GlossaryTermRef href="CDR0000044048" dictionary="Cancer.gov" audience="Patient">intramuscular</GlossaryTermRef>, or 
<GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">subcutaneous</GlossaryTermRef>).  In humans, it is
usually taken 
<GlossaryTermRef href="CDR0000044068" dictionary="Cancer.gov" audience="Patient">orally</GlossaryTermRef> as a pill (gel bead or <GlossaryTermRef href="CDR0000455334" dictionary="Cancer.gov" audience="Patient">capsule</GlossaryTermRef>), but 
intravenous <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusions</GlossaryTermRef> have been
given.<Reference refidx="4"/>  Coenzyme Q<Subscript>10</Subscript> is absorbed best with fat; therefore, lipid
preparations are better absorbed than the purified compound.<Reference refidx="2"/><Reference refidx="4"/> 
In human studies, supplementation <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">doses</GlossaryTermRef> and administration schedules have
varied, but usually have been in the range of 90 to 390 <GlossaryTermRef href="CDR0000044213" dictionary="Cancer.gov" audience="Patient">mg</GlossaryTermRef>/day.</Para><ReferenceSection><Citation idx="1" PMID="8241706" MedlineID="94060617">Crane FL, Sun IL, Sun EE: The essential functions of coenzyme Q. Clin Investig 71 (8 Suppl): S55-9, 1993.</Citation><Citation idx="2" PMID="10192685" MedlineID="99206903">Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999.</Citation><Citation idx="3" PMID="3836873" MedlineID="86274034">Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985.</Citation><Citation idx="4" PMID="10556981" MedlineID="20025952">Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999.</Citation><Citation idx="5">Beyer RE, Nordenbrand K, Ernster L: The role of coenzyme Q as a mitochondrial antioxidant: a short review. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 5. Elsevier Science Publishers B V  (Biomedical Division), 1986, pp 17-24.</Citation><Citation idx="6" PMID="8760864" MedlineID="96349137">Gordon M: Dietary antioxidants in disease prevention. Nat Prod Rep 13 (4): 265-73, 1996.</Citation><Citation idx="7" PMID="9250020" MedlineID="97393526">Palazzoni G, Pucello D, Littarru GP, et al.: Coenzyme Q10 and colorectal neoplasms in aged patients. Rays 22 (1 Suppl): 73-6, 1997 Jan-Mar.</Citation><Citation idx="8" PMID="7599208" MedlineID="95322475">Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271 (1): 195-204, 1995.</Citation><Citation idx="9" PMID="9636673" MedlineID="98300302">Yamamoto Y, Yamashita S, Fujisawa A, et al.: Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 247 (1): 166-70, 1998.</Citation><Citation idx="10" PMID="9266509" MedlineID="97411541">Yamamoto Y, Yamashita S: Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 18 (Suppl): S79-84, 1997.</Citation><Citation idx="11" PMID="8241707" MedlineID="94060618">Ernster L, Forsmark-Andrée P: Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 71 (8 Suppl): S60-5, 1993.</Citation><Citation idx="12" PMID="4218125" MedlineID="75129156">Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974.</Citation><Citation idx="13" PMID="9177262" MedlineID="97320411">Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997.</Citation><Citation idx="14" PMID="9760013" MedlineID="98430813">Jolliet P, Simon N, Barré J, et al.: Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 36 (9): 506-9, 1998.</Citation><Citation idx="15" PMID="7752841" MedlineID="95272334">Baggio E, Gandini R, Plancher AC, et al.: Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 15 (Suppl): s287-94, 1994.</Citation><Citation idx="16" PMID="667863" MedlineID="78212797">Cortes EP, Gupta M, Chou C, et al.: Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 62 (6): 887-91, 1978.</Citation><Citation idx="17" PMID="8476426" MedlineID="93236579">Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993.</Citation><Citation idx="18" PMID="7752832" MedlineID="95272325">Iarussi D, Auricchio U, Agretto A, et al.: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 15 (Suppl): s207-12, 1994.</Citation><Citation idx="19" PMID="7163631" MedlineID="83145727">Folkers K, Shizukuishi S, Takemura K, et al.: Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 38 (2): 335-8, 1982.</Citation><Citation idx="20" PMID="10079467" MedlineID="99179184">Complementary treatments highlighted at recent meeting. Oncology (Huntingt) 13 (2): 166, 1999.</Citation><Citation idx="21" PMID="5478631" MedlineID="71031213">Bliznakov E, Casey A, Premuzic E: Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia 26 (9): 953-4, 1970.</Citation><Citation idx="22" PMID="1673841" MedlineID="91222249">Folkers K, Hanioka T, Xia LJ, et al.: Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 176 (2): 786-91, 1991.</Citation><Citation idx="23" PMID="101414" MedlineID="79046139">Kawase I, Niitani H, Saijo N, et al.: Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice. Gann 69 (4): 493-7, 1978.</Citation><Citation idx="24" PMID="4510283" MedlineID="73096282">Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10  on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973.</Citation><Citation idx="25" PMID="4346875" MedlineID="73096163">Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972.</Citation><Citation idx="26">Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.</Citation><Citation idx="27" PMID="10416052" MedlineID="99344541">Barbieri B, Lund B, Lundström B, et al.: Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study. Biofactors 9 (2-4): 351-7, 1999.</Citation><Citation idx="28" PMID="7752835" MedlineID="95272328">Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994.</Citation><Citation idx="29" PMID="7908519" MedlineID="94197748">Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 199 (3): 1504-8, 1994.</Citation><Citation idx="30" PMID="7612003" MedlineID="95336438">Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995.</Citation><Citation idx="31" PMID="8702395" MedlineID="96295494">Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996.</Citation><Citation idx="32" PMID="9204686" MedlineID="97348702">Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997.</Citation><Citation idx="33" PMID="10416054" MedlineID="99344543">Hodges S, Hertz N, Lockwood K, et al.: CoQ10: could it have a role in cancer management? Biofactors 9 (2-4): 365-70, 1999.</Citation><Citation idx="34" PMID="653103" MedlineID="78179932">Folkers K, Porter TH, Bertino JR, et al.: Inhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. Res Commun Chem Pathol Pharmacol 19 (3): 485-90, 1978.</Citation></ReferenceSection></SummarySection><SummarySection id="_13"><Title>History</Title><Para id="_14"><GlossaryTermRef href="CDR0000346488" dictionary="Cancer.gov" audience="Patient">Coenzyme</GlossaryTermRef> Q<Subscript>10</Subscript> was first isolated in 1957,  and its
chemical structure (benzoquinone compound) was determined in 1958.<Reference refidx="1"/><Reference refidx="2"/>  Interest in coenzyme Q<Subscript>10</Subscript> as a <GlossaryTermRef href="CDR0000043985" dictionary="Cancer.gov" audience="Patient">therapeutic</GlossaryTermRef> agent in <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> 
began in 1961, when a <GlossaryTermRef href="CDR0000321364" dictionary="Cancer.gov" audience="Patient">deficiency</GlossaryTermRef> was noted in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> of both Swedish and
American cancer patients, especially in the blood of patients with <GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">breast
cancer</GlossaryTermRef>.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>  A subsequent <GlossaryTermRef href="CDR0000044195" dictionary="Cancer.gov" audience="Patient">study</GlossaryTermRef> showed a <GlossaryTermRef href="CDR0000044167" dictionary="Cancer.gov" audience="Patient">statistically
significant</GlossaryTermRef> relationship between the level of <GlossaryTermRef href="CDR0000045839" dictionary="Cancer.gov" audience="Patient">plasma</GlossaryTermRef> coenzyme Q<Subscript>10</Subscript>
deficiency and breast cancer <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef>.<Reference refidx="5"/>  Low blood levels of this
compound have been reported in patients with <GlossaryTermRef href="CDR0000045771" dictionary="Cancer.gov" audience="Patient">malignancies</GlossaryTermRef> other than breast
cancer, including <GlossaryTermRef href="CDR0000045795" dictionary="Cancer.gov" audience="Patient">myeloma</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphoma</GlossaryTermRef>, and cancers of the <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lung</GlossaryTermRef>,
 <GlossaryTermRef href="CDR0000046539" dictionary="Cancer.gov" audience="Patient">prostate</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046254" dictionary="Cancer.gov" audience="Patient">pancreas</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046462" dictionary="Cancer.gov" audience="Patient">colon</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046325" dictionary="Cancer.gov" audience="Patient">kidney</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000257519" dictionary="Cancer.gov" audience="Patient">head and neck</GlossaryTermRef>.<Reference refidx="2"/><Reference refidx="6"/><Reference refidx="7"/> 
Furthermore, decreased levels of coenzyme Q<Subscript>10</Subscript> have been detected in 
<GlossaryTermRef href="CDR0000045772" dictionary="Cancer.gov" audience="Patient">malignant</GlossaryTermRef> human <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissue</GlossaryTermRef>,<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/> but
increased levels have been reported as well.<Reference refidx="8"/></Para><Para id="_15">A large amount of <GlossaryTermRef href="CDR0000044512" dictionary="Cancer.gov" audience="Patient">laboratory</GlossaryTermRef> and <GlossaryTermRef href="CDR0000454774" dictionary="Cancer.gov" audience="Patient">animal</GlossaryTermRef> data on coenzyme Q<Subscript>10</Subscript> have
accumulated since 1962.<Reference refidx="2"/>  Research into cellular energy-producing mechanisms that involve this compound was awarded the Nobel Prize in
Chemistry in 1978.  Some of the accumulated data show that coenzyme
Q<Subscript>10</Subscript> stimulates animal <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune systems</GlossaryTermRef>, leading to higher <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibody</GlossaryTermRef> levels,<Reference refidx="13"/> greater numbers
and/or activities of <GlossaryTermRef href="CDR0000044054" dictionary="Cancer.gov" audience="Patient">macrophages</GlossaryTermRef> and 
<GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T cells</GlossaryTermRef> (T <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef>),<Reference refidx="13"/><Reference refidx="14"/> and increased
resistance to <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef>.<Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/>  Coenzyme Q<Subscript>10</Subscript> has also been
reported to increase IgG (<GlossaryTermRef href="CDR0000045725" dictionary="Cancer.gov" audience="Patient">immunoglobulin</GlossaryTermRef> G) antibody levels
and to increase the CD4 to CD8 T-cell ratio in humans.<Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/>  CD4 and CD8
are <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">proteins</GlossaryTermRef> found on the surface of T cells, with CD4 and CD8 identifying
 <GlossaryTermRef href="CDR0000044594" dictionary="Cancer.gov" audience="Patient">helper T cells</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045664" dictionary="Cancer.gov" audience="Patient">cytotoxic T cells</GlossaryTermRef>,
respectively; decreased CD4 to CD8 T-cell ratios have been reported for cancer
patients.<Reference refidx="21"/><Reference refidx="22"/>  Research subsequently delineated the <GlossaryTermRef href="CDR0000043997" dictionary="Cancer.gov" audience="Patient">antioxidant</GlossaryTermRef> properties
of coenzyme Q<Subscript>10</Subscript>.<Reference refidx="23"/><Reference refidx="24"/><Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/></Para><Para id="_16">Proposed mechanisms of action for coenzyme Q<Subscript>10</Subscript> that are relevant
to cancer include its essential function in cellular energy production and its
stimulation of the immune system (which may both be related), as well as
its role as an antioxidant.  Coenzyme Q<Subscript>10</Subscript> is essential to 
<GlossaryTermRef href="CDR0000043991" dictionary="Cancer.gov" audience="Patient">aerobic</GlossaryTermRef> energy production,<Reference refidx="1"/><Reference refidx="25"/><Reference refidx="28"/> and it has been suggested that increased cellular energy leads to
increased antibody synthesis in <GlossaryTermRef href="CDR0000045611" dictionary="Cancer.gov" audience="Patient">B cells</GlossaryTermRef>
(<GlossaryTermRef href="CDR0000044953" dictionary="Cancer.gov" audience="Patient">B lymphocytes</GlossaryTermRef>).<Reference refidx="6"/><Reference refidx="18"/>  As noted previously (<SummaryRef href="CDR0000062979#_5" url="/about-cancer/treatment/cam/hp/coenzyme-q10-pdq">General Information section</SummaryRef>),
coenzyme Q<Subscript>10</Subscript> can also behave as an antioxidant.<Reference refidx="1"/><Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/><Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/>  In this capacity, coenzyme Q<Subscript>10</Subscript> is thought to stabilize cell
membranes (<GlossaryTermRef href="CDR0000046068" dictionary="Cancer.gov" audience="Patient">lipid</GlossaryTermRef>-containing structures essential to maintaining cell
integrity) and to prevent <GlossaryTermRef href="CDR0000044030" dictionary="Cancer.gov" audience="Patient">free radical</GlossaryTermRef> damage to other important cellular
components.<Reference refidx="1"/><Reference refidx="25"/><Reference refidx="27"/><Reference refidx="32"/>  Free radical damage to <GlossaryTermRef href="CDR0000044393" dictionary="Genetics" audience="Health professional">DNA</GlossaryTermRef> (and possibly to
other cellular  <GlossaryTermRef href="CDR0000045065" dictionary="Cancer.gov" audience="Patient">molecules</GlossaryTermRef>) may be a factor in cancer development.<Reference refidx="11"/><Reference refidx="23"/><Reference refidx="30"/><Reference refidx="33"/><Reference refidx="34"/><Reference refidx="35"/><Reference refidx="36"/></Para><ReferenceSection><Citation idx="1" PMID="10192685" MedlineID="99206903">Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999.</Citation><Citation idx="2" PMID="9177262" MedlineID="97320411">Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997.</Citation><Citation idx="3" PMID="7612003" MedlineID="95336438">Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995.</Citation><Citation idx="4" PMID="9204686" MedlineID="97348702">Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997.</Citation><Citation idx="5" PMID="9760013" MedlineID="98430813">Jolliet P, Simon N, Barré J, et al.: Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 36 (9): 506-9, 1998.</Citation><Citation idx="6" PMID="4218125" MedlineID="75129156">Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974.</Citation><Citation idx="7" PMID="8702395" MedlineID="96295494">Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996.</Citation><Citation idx="8" PMID="5225398" MedlineID="67081708">Chipperfield B: Ubiquinone concentrations in some tumour-bearing tissues. Ubiquinone concentrations in tumours and some normal tissues in man. Nature 209 (29): 1207-8, 1966.</Citation><Citation idx="9" PMID="2538136" MedlineID="89166334">Eggens I, Elmberger PG, Löw P: Polyisoprenoid, cholesterol and ubiquinone levels in human hepatocellular carcinomas. Br J Exp Pathol 70 (1): 83-92, 1989.</Citation><Citation idx="10" PMID="9537635" MedlineID="98196985">Mano T, Iwase K, Hayashi R, et al.: Vitamin E and coenzyme Q concentrations in the thyroid tissues of patients with various thyroid disorders. Am J Med Sci 315 (4): 230-2, 1998.</Citation><Citation idx="11" PMID="8751964" MedlineID="96354729">Picardo M, Grammatico P, Roccella F, et al.: Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 107 (3): 322-6, 1996.</Citation><Citation idx="12" PMID="10936586" MedlineID="20396063">Portakal O, Ozkaya O, Erden Inal M, et al.: Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 33 (4): 279-84, 2000.</Citation><Citation idx="13" PMID="5478631" MedlineID="71031213">Bliznakov E, Casey A, Premuzic E: Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia 26 (9): 953-4, 1970.</Citation><Citation idx="14" PMID="101414" MedlineID="79046139">Kawase I, Niitani H, Saijo N, et al.: Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice. Gann 69 (4): 493-7, 1978.</Citation><Citation idx="15" PMID="4510283" MedlineID="73096282">Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10  on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973.</Citation><Citation idx="16" PMID="4346875" MedlineID="73096163">Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972.</Citation><Citation idx="17">Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.</Citation><Citation idx="18" PMID="7163631" MedlineID="83145727">Folkers K, Shizukuishi S, Takemura K, et al.: Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 38 (2): 335-8, 1982.</Citation><Citation idx="19" PMID="1673841" MedlineID="91222249">Folkers K, Hanioka T, Xia LJ, et al.: Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 176 (2): 786-91, 1991.</Citation><Citation idx="20" PMID="10416052" MedlineID="99344541">Barbieri B, Lund B, Lundström B, et al.: Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study. Biofactors 9 (2-4): 351-7, 1999.</Citation><Citation idx="21" PMID="2957843" MedlineID="87320747">Shaw M, Ray P, Rubenstein M, et al.: Lymphocyte subsets in urologic cancer patients. Urol Res 15 (3): 181-5, 1987.</Citation><Citation idx="22" PMID="3494139" MedlineID="87170150">Tsuyuguchi I, Shiratsuchi H, Fukuoka M: T-lymphocyte subsets in primary lung cancer. Jpn J Clin Oncol 17 (1): 13-7, 1987.</Citation><Citation idx="23" PMID="9636673" MedlineID="98300302">Yamamoto Y, Yamashita S, Fujisawa A, et al.: Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 247 (1): 166-70, 1998.</Citation><Citation idx="24" PMID="9266509" MedlineID="97411541">Yamamoto Y, Yamashita S: Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 18 (Suppl): S79-84, 1997.</Citation><Citation idx="25" PMID="8241706" MedlineID="94060617">Crane FL, Sun IL, Sun EE: The essential functions of coenzyme Q. Clin Investig 71 (8 Suppl): S55-9, 1993.</Citation><Citation idx="26" PMID="10556981" MedlineID="20025952">Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999.</Citation><Citation idx="27" PMID="8241707" MedlineID="94060618">Ernster L, Forsmark-Andrée P: Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 71 (8 Suppl): S60-5, 1993.</Citation><Citation idx="28" PMID="3836873" MedlineID="86274034">Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985.</Citation><Citation idx="29">Beyer RE, Nordenbrand K, Ernster L: The role of coenzyme Q as a mitochondrial antioxidant: a short review. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 5. Elsevier Science Publishers B V  (Biomedical Division), 1986, pp 17-24.</Citation><Citation idx="30" PMID="8760864" MedlineID="96349137">Gordon M: Dietary antioxidants in disease prevention. Nat Prod Rep 13 (4): 265-73, 1996.</Citation><Citation idx="31" PMID="9250020" MedlineID="97393526">Palazzoni G, Pucello D, Littarru GP, et al.: Coenzyme Q10 and colorectal neoplasms in aged patients. Rays 22 (1 Suppl): 73-6, 1997 Jan-Mar.</Citation><Citation idx="32" PMID="7599208" MedlineID="95322475">Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271 (1): 195-204, 1995.</Citation><Citation idx="33" PMID="10601883" MedlineID="20071154">Aust AE, Eveleigh JF: Mechanisms of DNA oxidation. Proc Soc Exp Biol Med 222 (3): 246-52, 1999.</Citation><Citation idx="34" PMID="10415430" MedlineID="99346234">Halliwell B: Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res 443 (1-2): 37-52, 1999.</Citation><Citation idx="35" PMID="10415429" MedlineID="99346233">Burcham PC: Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res 443 (1-2): 11-36, 1999.</Citation><Citation idx="36" PMID="8695238" MedlineID="96245996">Dreher D, Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer 32A (1): 30-8, 1996.</Citation></ReferenceSection></SummarySection><SummarySection id="_17"><Title>Laboratory/Animal/Preclinical Studies</Title><Para id="_18"><GlossaryTermRef href="CDR0000044512" dictionary="Cancer.gov" audience="Patient">Laboratory</GlossaryTermRef> work on <GlossaryTermRef href="CDR0000346488" dictionary="Cancer.gov" audience="Patient">coenzyme</GlossaryTermRef> Q<Subscript>10</Subscript> has focused primarily on its
structure and its function in <GlossaryTermRef href="CDR0000044008" dictionary="Cancer.gov" audience="Patient">cell respiration</GlossaryTermRef>.  Studies in <GlossaryTermRef href="CDR0000454774" dictionary="Cancer.gov" audience="Patient">animals</GlossaryTermRef> have
demonstrated that coenzyme Q<Subscript>10</Subscript> is capable of stimulating the <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune
system</GlossaryTermRef>, with treated animals showing increased resistance to <GlossaryTermRef href="CDR0000044080" dictionary="Cancer.gov" audience="Patient">protozoal</GlossaryTermRef> <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infections</GlossaryTermRef> <Reference refidx="1"/><Reference refidx="2"/> and to <GlossaryTermRef href="CDR0000044629" dictionary="Cancer.gov" audience="Patient">viral</GlossaryTermRef> 
and chemically-induced <GlossaryTermRef href="CDR0000045801" dictionary="Cancer.gov" audience="Patient">neoplasia</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>  Early
studies of coenzyme Q<Subscript>10</Subscript> showed increased <GlossaryTermRef href="CDR0000044035" dictionary="Cancer.gov" audience="Patient">hematopoiesis</GlossaryTermRef> (the formation of new
 <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> cells) in monkeys,<Reference refidx="4"/><Reference refidx="5"/>  rabbits,<Reference refidx="6"/> and
poultry.<Reference refidx="5"/>  Coenzyme Q<Subscript>10</Subscript> demonstrated a protective
effect on the heart muscle of mice, rats, and rabbits given the <GlossaryTermRef href="CDR0000044916" dictionary="Cancer.gov" audience="Patient">anthracycline</GlossaryTermRef> 
anticancer drug  <GlossaryTermRef href="CDR0000560140" dictionary="Cancer.gov" audience="Patient">doxorubicin</GlossaryTermRef>.<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>  Although another study confirmed this
protective effect with <GlossaryTermRef href="CDR0000046339" dictionary="Cancer.gov" audience="Patient">intraperitoneal</GlossaryTermRef> administration of doxorubicin in mice,
it failed to demonstrate a protective effect when the anthracycline was given 
<GlossaryTermRef href="CDR0000046682" dictionary="Cancer.gov" audience="Patient">intravenously</GlossaryTermRef>, which is the route of administration in humans.<Reference refidx="13"/> 
</Para><Para id="_75">Researchers in one study sounded a cautionary note when they found that
coadministration of coenzyme Q<Subscript>10</Subscript> and <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef> decreased the
effectiveness of the radiation therapy.<Reference refidx="14"/>  In this study, mice inoculated with
human <GlossaryTermRef href="CDR0000045327" dictionary="Cancer.gov" audience="Patient">small cell lung cancer</GlossaryTermRef> cells
(a <GlossaryTermRef href="CDR0000044095" dictionary="Cancer.gov" audience="Patient">xenograft</GlossaryTermRef> study), and then given
coenzyme Q<Subscript>10</Subscript> and single-<GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">dose</GlossaryTermRef> radiation therapy, showed
substantially less inhibition of <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> growth than mice in the <GlossaryTermRef href="CDR0000044149" dictionary="Cancer.gov" audience="Patient">control group</GlossaryTermRef> 
that were treated with radiation therapy alone.  Since radiation leads to the
production of <GlossaryTermRef href="CDR0000044030" dictionary="Cancer.gov" audience="Patient">free radicals</GlossaryTermRef>, and since <GlossaryTermRef href="CDR0000043997" dictionary="Cancer.gov" audience="Patient">antioxidants</GlossaryTermRef> protect against free
radical damage, the effect in this study might be explained by coenzyme
Q<Subscript>10</Subscript> acting as an antioxidant.  As noted previously, there is some evidence from
laboratory and animal studies that <GlossaryTermRef href="CDR0000044919" dictionary="Cancer.gov" audience="Patient">analogs</GlossaryTermRef> of coenzyme Q<Subscript>10</Subscript> may
have direct anticancer activity.<Reference refidx="15"/><Reference refidx="16"/> See the <SummaryRef href="CDR0000062979#_5" url="/about-cancer/treatment/cam/hp/coenzyme-q10-pdq">General Information</SummaryRef> section.</Para><ReferenceSection><Citation idx="1" PMID="4346875" MedlineID="73096163">Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972.</Citation><Citation idx="2">Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.</Citation><Citation idx="3" PMID="4510283" MedlineID="73096282">Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10  on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973.</Citation><Citation idx="4" PMID="9177262" MedlineID="97320411">Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997.</Citation><Citation idx="5" PMID="8476426" MedlineID="93236579">Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993.</Citation><Citation idx="6" PMID="6078061" MedlineID="68102329">Ludwig FC, Elashoff RM, Smith JL, et al.: Response of the bone marrow of the vitamin E-deficient rabbit to coenzyme Q and vitamin E. Scand J Haematol 4 (4): 292-300, 1967.</Citation><Citation idx="7" PMID="441512" MedlineID="79181315">Choe JY, Combs AB, Folkers K: Prevention by coenzyme Q10 of the electrocardiographic changes induced by adriamycin in rats. Res Commun Chem Pathol Pharmacol 23 (1): 199-202, 1979.</Citation><Citation idx="8" PMID="928953" MedlineID="78054223">Combs AB, Choe JY, Truong DH, et al.: Reduction by coenzyme Q10 of the acute toxicity of adriamycin in mice. Res Commun Chem Pathol Pharmacol 18 (3): 565-8, 1977.</Citation><Citation idx="9" PMID="283424" MedlineID="79116282">Folkers K, Choe JY, Combs AB: Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat. Proc Natl Acad Sci U S A 75 (10): 5178-80, 1978.</Citation><Citation idx="10" PMID="6928034" MedlineID="80097832">Lubawy WC, Dallam RA, Hurley LH: Protection against anthramycin-induced toxicity in mice by coenzyme Q10. J Natl Cancer Inst 64 (1): 105-9, 1980.</Citation><Citation idx="11" PMID="8312867" MedlineID="94146746">Shinozawa S, Gomita Y, Araki Y: Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull 16 (11): 1114-7, 1993.</Citation><Citation idx="12" PMID="7112605" MedlineID="82278215">Usui T, Ishikura H, Izumi Y, et al.: Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicol Lett 12 (1): 75-82, 1982.</Citation><Citation idx="13" PMID="7414051" MedlineID="81014900">Shaeffer J, El-Mahdi AM, Nichols RK: Coenzyme Q10 and adriamycin toxicity in mice. Res Commun Chem Pathol Pharmacol 29 (2): 309-15, 1980.</Citation><Citation idx="14" PMID="9821311" MedlineID="99038752">Lund EL, Quistorff B, Spang-Thomsen M, et al.: Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha) 43 (5): 505-6, 1998.</Citation><Citation idx="15" PMID="4218125" MedlineID="75129156">Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974.</Citation><Citation idx="16" PMID="653103" MedlineID="78179932">Folkers K, Porter TH, Bertino JR, et al.: Inhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. Res Commun Chem Pathol Pharmacol 19 (3): 485-90, 1978.</Citation></ReferenceSection></SummarySection><SummarySection id="_19"><Title>Human/Clinical Studies</Title><Para id="_76"><GlossaryTermRef href="CDR0000044195" dictionary="Cancer.gov" audience="Patient">Clinical studies</GlossaryTermRef> on the use of coenzyme Q<Subscript>10</Subscript> to prevent <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> treatment, treat side effects of cancer treatment, and/or as a treatment for cancer are very limited. Importantly, <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trials</GlossaryTermRef> that examined the use of coenzyme Q<Subscript>10</Subscript> during cancer treatment to prevent toxicities have not followed patients for long-term outcomes to determine whether coenzyme Q<Subscript>10</Subscript> decreased the <GlossaryTermRef href="CDR0000346517" dictionary="Cancer.gov" audience="Patient">efficacy</GlossaryTermRef> of cancer treatments (e.g., <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy)</GlossaryTermRef>. A recent <GlossaryTermRef href="CDR0000286105" dictionary="Cancer.gov" audience="Patient">observational study</GlossaryTermRef> conducted with 1,134 patients with <GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">breast cancer</GlossaryTermRef> enrolled in an <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef> multi-institution clinical trial (<ProtocolRef nct_id="NCT00070564">SWOG S0221</ProtocolRef>) suggested that the use of <GlossaryTermRef href="CDR0000043997" dictionary="Cancer.gov" audience="Patient">antioxidant</GlossaryTermRef> supplements, including coenzyme Q<Subscript>10</Subscript>, prior to and during cancer treatment may be associated with increased <GlossaryTermRef href="CDR0000045861" dictionary="Cancer.gov" audience="Patient">recurrence</GlossaryTermRef> rates and decreased survival.<Reference refidx="1"/></Para><SummarySection id="_64"><Title>Symptom and Side Effect Management</Title><SummarySection id="_65"><Title>Cardiac toxicity</Title><Para id="_66">In view of promising results from <GlossaryTermRef href="CDR0000454774" dictionary="Cancer.gov" audience="Patient">animal studies</GlossaryTermRef>, coenzyme
Q<Subscript>10</Subscript> was tested as a protective agent against <GlossaryTermRef href="CDR0000045634" dictionary="Cancer.gov" audience="Patient">cardiac</GlossaryTermRef> toxicity that was observed in cancer
patients treated with the <GlossaryTermRef href="CDR0000044916" dictionary="Cancer.gov" audience="Patient">anthracycline</GlossaryTermRef> drug <GlossaryTermRef href="CDR0000560140" dictionary="Cancer.gov" audience="Patient">doxorubicin</GlossaryTermRef>.  It has been
postulated that  doxorubicin interferes with energy-generating <GlossaryTermRef href="CDR0000044124" dictionary="Cancer.gov" audience="Patient">biochemical
reactions</GlossaryTermRef> that involve coenzyme Q<Subscript>10</Subscript> in heart muscle <GlossaryTermRef href="CDR0000044060" dictionary="Cancer.gov" audience="Patient">mitochondria</GlossaryTermRef> 
and that this interference can be overcome by coenzyme Q<Subscript>10</Subscript> <GlossaryTermRef href="CDR0000045916" dictionary="Cancer.gov" audience="Patient">supplementation</GlossaryTermRef>.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>  Studies with adults and children, including the
aforementioned <GlossaryTermRef href="CDR0000045858" dictionary="Cancer.gov" audience="Patient">randomized trial</GlossaryTermRef>, have confirmed the decrease in cardiac
toxicity observed in animal studies.<Reference refidx="2"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/> A randomized trial <Reference refidx="7"/> of 20 patients tested the ability of coenzyme Q<Subscript>10</Subscript> to reduce <GlossaryTermRef href="CDR0000044004" dictionary="Cancer.gov" audience="Patient">cardiotoxicity</GlossaryTermRef> caused by anthracycline drugs.</Para></SummarySection><SummarySection id="_67"><Title>Fatigue</Title><Para id="_68">Two randomized, <GlossaryTermRef href="CDR0000044014" dictionary="Cancer.gov" audience="Patient">controlled trials</GlossaryTermRef> have explored the potential of coenzyme Q<Subscript>10</Subscript>-containing supplements to prevent or treat <GlossaryTermRef href="CDR0000321374" dictionary="Cancer.gov" audience="Patient">fatigue</GlossaryTermRef> in patients who received cancer therapy. A randomized, <GlossaryTermRef href="CDR0000044840" dictionary="Cancer.gov" audience="Patient">placebo-controlled</GlossaryTermRef> trial of 236 patients with breast cancer  who received <GlossaryTermRef href="CDR0000045587" dictionary="Cancer.gov" audience="Patient">adjuvant chemotherapy</GlossaryTermRef> with or without radiation therapy concluded that coenzyme Q<Subscript>10</Subscript> at a daily <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">dose</GlossaryTermRef> of 300 <GlossaryTermRef href="CDR0000044213" dictionary="Cancer.gov" audience="Patient">mg</GlossaryTermRef> combined with 300 <GlossaryTermRef href="CDR0000044764" dictionary="Cancer.gov" audience="Patient">IU</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045023" dictionary="Cancer.gov" audience="Patient">vitamin E</GlossaryTermRef>, divided into three doses, did not prevent treatment-induced worsening of mean fatigue levels or <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef> after 24 weeks of supplementation.<Reference refidx="8"/> Another smaller trial (N = 59) used a daily <GlossaryTermRef href="CDR0000478733" dictionary="Cancer.gov" audience="Patient">administration</GlossaryTermRef> of a different supplement that contained coenzyme Q<Subscript>10</Subscript> (30 mg) along with branched-chain <GlossaryTermRef href="CDR0000446104" dictionary="Cancer.gov" audience="Patient">amino acids</GlossaryTermRef> (2,500 mg) and <GlossaryTermRef href="CDR0000321377" dictionary="Cancer.gov" audience="Patient">L-carnitine</GlossaryTermRef> (50 mg). All patients received adjuvant chemotherapy, but none received radiation therapy during the 21 days of the trial. The results of this trial also failed to show a significant difference in the mean fatigue levels between the treatment group and the <GlossaryTermRef href="CDR0000044149" dictionary="Cancer.gov" audience="Patient">control group</GlossaryTermRef>, though a <GlossaryTermRef href="CDR0000044167" dictionary="Cancer.gov" audience="Patient">statistically significant</GlossaryTermRef> benefit was seen for the study’s <GlossaryTermRef href="CDR0000044163" dictionary="Cancer.gov" audience="Patient">primary endpoint</GlossaryTermRef> (worst level of fatigue during the past 24 hours).<Reference refidx="9"/></Para></SummarySection></SummarySection><SummarySection id="_69"><Title>Cancer Treatment</Title><Para id="_70">The use of <GlossaryTermRef href="CDR0000346488" dictionary="Cancer.gov" audience="Patient">coenzyme</GlossaryTermRef> Q<Subscript>10</Subscript> as a treatment for cancer in humans has
been investigated in only a limited manner.  In view of observations that <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> levels of coenzyme
Q<Subscript>10</Subscript> are frequently reduced in cancer patients,<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/> supplementation with this <GlossaryTermRef href="CDR0000422394" dictionary="Cancer.gov" audience="Patient">compound</GlossaryTermRef> has been tested in patients
undergoing <GlossaryTermRef href="CDR0000044950" dictionary="Cancer.gov" audience="Patient">conventional treatment</GlossaryTermRef>.  An open-label, <GlossaryTermRef href="CDR0000044066" dictionary="Cancer.gov" audience="Patient">nonblinded</GlossaryTermRef>, uncontrolled clinical study
in Denmark followed 32 patients with breast cancer  for 18 months.<Reference refidx="15"/>  The disease
had spread to the <GlossaryTermRef href="CDR0000045607" dictionary="Cancer.gov" audience="Patient">axillary lymph nodes</GlossaryTermRef>, and an
unreported number of patients had distant <GlossaryTermRef href="CDR0000046710" dictionary="Cancer.gov" audience="Patient">metastases</GlossaryTermRef>.  Patients received 
antioxidant supplementation (<GlossaryTermRef href="CDR0000439435" dictionary="Cancer.gov" audience="Patient">vitamin C</GlossaryTermRef>, vitamin E, and <GlossaryTermRef href="CDR0000045328" dictionary="Cancer.gov" audience="Patient">beta carotene</GlossaryTermRef>), other
 <GlossaryTermRef href="CDR0000044744" dictionary="Cancer.gov" audience="Patient">vitamins</GlossaryTermRef> and trace <GlossaryTermRef href="CDR0000045787" dictionary="Cancer.gov" audience="Patient">minerals</GlossaryTermRef>, essential <GlossaryTermRef href="CDR0000045689" dictionary="Cancer.gov" audience="Patient">fatty acids</GlossaryTermRef>, and coenzyme
Q<Subscript>10</Subscript> (at a dose of 90 mg/day), in addition to <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard
therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">surgery</GlossaryTermRef>, radiation therapy, and chemotherapy, with or without <GlossaryTermRef href="CDR0000509341" dictionary="Cancer.gov" audience="Patient">tamoxifen</GlossaryTermRef>).  Patients were seen every
3 months to <GlossaryTermRef href="CDR0000454803" dictionary="Cancer.gov" audience="Patient">monitor</GlossaryTermRef> disease status (<GlossaryTermRef href="CDR0000045850" dictionary="Cancer.gov" audience="Patient">progressive disease</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045861" dictionary="Cancer.gov" audience="Patient">recurrence</GlossaryTermRef>), and if there was a
suspicion of recurrence, <GlossaryTermRef href="CDR0000045996" dictionary="Cancer.gov" audience="Patient">mammography</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046499" dictionary="Cancer.gov" audience="Patient">bone scan</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-ray</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045164" dictionary="Cancer.gov" audience="Patient">biopsy</GlossaryTermRef> was performed.  The <GlossaryTermRef href="CDR0000044301" dictionary="Cancer.gov" audience="Patient">survival rate</GlossaryTermRef> for
the study period was 100% (four deaths were expected).  Six
patients were reported to show some evidence of <GlossaryTermRef href="CDR0000045867" dictionary="Cancer.gov" audience="Patient">remission</GlossaryTermRef>; however, incomplete clinical
data were provided and information suggestive of remission was presented for
only three of  six patients.  None of the six patients had evidence of
further metastases.  For all 32 patients, decreased use of painkillers,
improved <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>, and an
absence of weight loss were reported.  Whether painkiller use and quality of
life were measured objectively (e.g., from pharmacy records and validated
questionnaires, respectively) or subjectively (from patient self-reports) was
not specified.</Para><Para id="_71">In a <GlossaryTermRef href="CDR0000044671" dictionary="Cancer.gov" audience="Patient">follow-up</GlossaryTermRef> study, one of six patients with a reported remission and
one new patient were treated for several months with higher doses of coenzyme
Q<Subscript>10</Subscript> (390 mg/day and 300 mg/day, respectively).<Reference refidx="16"/>  Surgical
removal of the <GlossaryTermRef href="CDR0000045847" dictionary="Cancer.gov" audience="Patient">primary</GlossaryTermRef> breast tumor in both patients had been incomplete. 
After 3 to 4 months of high-level coenzyme Q<Subscript>10</Subscript> supplementation,
both patients appeared to experience complete 
<GlossaryTermRef href="CDR0000046039" dictionary="Cancer.gov" audience="Patient">regression</GlossaryTermRef> of their <GlossaryTermRef href="CDR0000045869" dictionary="Cancer.gov" audience="Patient">residual</GlossaryTermRef> breast
tumors (assessed by clinical examination and mammography).  It should be noted
that a different patient identifier was used in the follow-up study for the
patient who had participated in the original study.  Therefore, it is
impossible to determine which of the six patients with a reported remission
took part in the follow-up study.  In the follow-up study report, the
researchers noted that all 32 patients from the original study remained alive
at 24 months of <GlossaryTermRef href="CDR0000045981" dictionary="Cancer.gov" audience="Patient">observation</GlossaryTermRef>, whereas six deaths had been expected.<Reference refidx="16"/></Para><Para id="_72">In another report by the same <GlossaryTermRef href="CDR0000044685" dictionary="Cancer.gov" audience="Patient">investigators</GlossaryTermRef>, three patients with breast cancer 
who received high-dose coenzyme Q<Subscript>10</Subscript>
(390 mg/day) were followed for a total of 3 to 5 years.<Reference refidx="11"/>  One patient had <GlossaryTermRef href="CDR0000045651" dictionary="Cancer.gov" audience="Patient">complete remission</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045316" dictionary="Cancer.gov" audience="Patient">liver metastases</GlossaryTermRef> (determined by clinical examination and <GlossaryTermRef href="CDR0000045557" dictionary="Cancer.gov" audience="Patient">ultrasonography</GlossaryTermRef>), one patient had 
remission of a tumor that had spread to the <GlossaryTermRef href="CDR0000044996" dictionary="Cancer.gov" audience="Patient">chest wall</GlossaryTermRef> (determined by clinical
examination and <GlossaryTermRef href="CDR0000304687" dictionary="Cancer.gov" audience="Patient">chest x-ray</GlossaryTermRef>), and one patient had no <GlossaryTermRef href="CDR0000044608" dictionary="Cancer.gov" audience="Patient">microscopic</GlossaryTermRef> 
evidence of remaining tumor after a <GlossaryTermRef href="CDR0000045777" dictionary="Cancer.gov" audience="Patient">mastectomy</GlossaryTermRef> (determined by biopsy of the
tumor bed).</Para><Para id="_73">All three of the above-mentioned human studies <Reference refidx="11"/><Reference refidx="15"/><Reference refidx="16"/> had important design
flaws that could have influenced their outcome.  Study weaknesses include the
absence of a control group (i.e., all patients received coenzyme
Q<Subscript>10</Subscript>), possible <GlossaryTermRef href="CDR0000044087" dictionary="Cancer.gov" audience="Patient">selection
bias</GlossaryTermRef> in the follow-up investigations, and multiple confounding variables
(i.e., patients received a variety of supplements in addition to coenzyme
Q<Subscript>10</Subscript> and received standard therapy either during or
immediately before supplementation with coenzyme Q<Subscript>10</Subscript>).  Thus, it is
impossible to determine whether any of the beneficial results was directly
related to coenzyme Q<Subscript>10</Subscript> therapy.</Para><Para id="_74"><GlossaryTermRef href="CDR0000043995" dictionary="Cancer.gov" audience="Patient">Anecdotal reports</GlossaryTermRef> of coenzyme Q<Subscript>10</Subscript> lengthening the survival of
patients with <GlossaryTermRef href="CDR0000044074" dictionary="Cancer.gov" audience="Patient">pancreatic</GlossaryTermRef>, <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lung</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044083" dictionary="Cancer.gov" audience="Patient">rectal</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046317" dictionary="Cancer.gov" audience="Patient">laryngeal</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046462" dictionary="Cancer.gov" audience="Patient">colon</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000046539" dictionary="Cancer.gov" audience="Patient">prostate</GlossaryTermRef> cancers
also exist in the peer-reviewed scientific literature.<Reference refidx="6"/>  The patients
described in these reports also received therapies other than coenzyme
Q<Subscript>10</Subscript>, including chemotherapy, radiation therapy, and surgery.</Para></SummarySection><SummarySection id="_TrialSearch_19_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_19_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="31855498">Ambrosone CB, Zirpoli GR, Hutson AD, et al.: Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol 38 (8): 804-814, 2020.</Citation><Citation idx="2" PMID="667863" MedlineID="78212797">Cortes EP, Gupta M, Chou C, et al.: Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 62 (6): 887-91, 1978.</Citation><Citation idx="3" PMID="7112605" MedlineID="82278215">Usui T, Ishikura H, Izumi Y, et al.: Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicol Lett 12 (1): 75-82, 1982.</Citation><Citation idx="4" PMID="4152017" MedlineID="74263515">Iwamoto Y, Hansen IL, Porter TH, et al.: Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun 58 (3): 633-8, 1974.</Citation><Citation idx="5" PMID="3836873" MedlineID="86274034">Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985.</Citation><Citation idx="6" PMID="8476426" MedlineID="93236579">Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993.</Citation><Citation idx="7" PMID="7752832" MedlineID="95272325">Iarussi D, Auricchio U, Agretto A, et al.: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 15 (Suppl): s207-12, 1994.</Citation><Citation idx="8" PMID="22682875">Lesser GJ, Case D, Stark N, et al.: A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol 11 (1): 31-42, 2013.</Citation><Citation idx="9" PMID="26105516">Iwase S, Kawaguchi T, Yotsumoto D, et al.: Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). Support Care Cancer 24 (2): 637-646, 2016.</Citation><Citation idx="10" PMID="9177262" MedlineID="97320411">Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997.</Citation><Citation idx="11" PMID="7612003" MedlineID="95336438">Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995.</Citation><Citation idx="12" PMID="8702395" MedlineID="96295494">Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996.</Citation><Citation idx="13" PMID="9204686" MedlineID="97348702">Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997.</Citation><Citation idx="14" PMID="33547884">Shidal C, Yoon HS, Zheng W, et al.: Prospective study of plasma levels of coenzyme Q10 and lung cancer risk in a low-income population in the Southeastern United States. Cancer Med 10 (4): 1439-1447, 2021.</Citation><Citation idx="15" PMID="7752835" MedlineID="95272328">Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994.</Citation><Citation idx="16" PMID="7908519" MedlineID="94197748">Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 199 (3): 1504-8, 1994.</Citation></ReferenceSection></SummarySection><SummarySection id="_27"><Title>Adverse Effects</Title><Para id="_28">No serious <GlossaryTermRef href="CDR0000043986" dictionary="Cancer.gov" audience="Patient">toxicity</GlossaryTermRef> associated with the use of <GlossaryTermRef href="CDR0000346488" dictionary="Cancer.gov" audience="Patient">coenzyme</GlossaryTermRef> Q<Subscript>10</Subscript> has
been reported.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>  <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">Doses</GlossaryTermRef> of 100 <GlossaryTermRef href="CDR0000044213" dictionary="Cancer.gov" audience="Patient">mg</GlossaryTermRef>/day or
higher have caused mild <GlossaryTermRef href="CDR0000044043" dictionary="Cancer.gov" audience="Patient">insomnia</GlossaryTermRef> in
some individuals.  <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">Liver</GlossaryTermRef> <GlossaryTermRef href="CDR0000046081" dictionary="Cancer.gov" audience="Patient">enzyme</GlossaryTermRef> elevation has been detected in
patients taking doses of 300 mg/day for extended periods of time,
but no liver toxicity has been reported.<Reference refidx="1"/>  Researchers in one 
<GlossaryTermRef href="CDR0000044005" dictionary="Cancer.gov" audience="Patient">cardiovascular</GlossaryTermRef> <GlossaryTermRef href="CDR0000044195" dictionary="Cancer.gov" audience="Patient">study</GlossaryTermRef> reported that coenzyme Q<Subscript>10</Subscript> caused rashes,
 <GlossaryTermRef href="CDR0000390302" dictionary="Cancer.gov" audience="Patient">nausea</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000044027" dictionary="Cancer.gov" audience="Patient">epigastric</GlossaryTermRef> (upper
 <GlossaryTermRef href="CDR0000046684" dictionary="Cancer.gov" audience="Patient">abdominal</GlossaryTermRef>) pain that required withdrawal of a small number of patients from
the study.<Reference refidx="5"/>  Other reported <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> have included dizziness, 
<GlossaryTermRef href="CDR0000044077" dictionary="Cancer.gov" audience="Patient">photophobia</GlossaryTermRef> (abnormal visual
sensitivity to light), irritability,<Reference refidx="5"/> headache, heartburn, and
 <GlossaryTermRef href="CDR0000321374" dictionary="Cancer.gov" audience="Patient">fatigue</GlossaryTermRef>.<Reference refidx="6"/></Para><Para id="_77">In a <GlossaryTermRef href="CDR0000044079" dictionary="Cancer.gov" audience="Patient">prospective</GlossaryTermRef> study that explored the  association between supplement use and <GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">breast cancer</GlossaryTermRef> outcomes (<ProtocolRef nct_id="NCT00070564">SWOG S0221</ProtocolRef>), the use of any <GlossaryTermRef href="CDR0000043997" dictionary="Cancer.gov" audience="Patient">antioxidant</GlossaryTermRef> supplement before and during treatment–including coenzyme Q<Subscript>10</Subscript>, <GlossaryTermRef href="CDR0000045248" dictionary="Cancer.gov" audience="Patient">vitamin A</GlossaryTermRef>, <GlossaryTermRef href="CDR0000439435" dictionary="Cancer.gov" audience="Patient">vitamin C</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045023" dictionary="Cancer.gov" audience="Patient">vitamin E</GlossaryTermRef>, and carotenoids–was associated with a trend showing an increased hazard of <GlossaryTermRef href="CDR0000045861" dictionary="Cancer.gov" audience="Patient">recurrence</GlossaryTermRef> (adjusted hazard ratio, 1.41; confidence interval, 0.98–2.04, <Emphasis>P</Emphasis> = .06).<Reference refidx="7"/></Para><Para id="_29">Certain <GlossaryTermRef href="CDR0000046068" dictionary="Cancer.gov" audience="Patient">lipid</GlossaryTermRef>-lowering drugs, such as the <GlossaryTermRef href="CDR0000390255" dictionary="Cancer.gov" audience="Patient">statins</GlossaryTermRef> (lovastatin,
 <GlossaryTermRef href="CDR0000618548" dictionary="Cancer.gov" audience="Patient">pravastatin</GlossaryTermRef>, and simvastatin) and gemfibrozil, as well as <GlossaryTermRef href="CDR0000044068" dictionary="Cancer.gov" audience="Patient">oral</GlossaryTermRef> agents that
lower <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> sugar, such as glyburide and tolazamide, cause a decrease in 
<GlossaryTermRef href="CDR0000044088" dictionary="Cancer.gov" audience="Patient">serum</GlossaryTermRef> levels of coenzyme Q<Subscript>10</Subscript>
 and reduce the effects of coenzyme Q<Subscript>10</Subscript> <GlossaryTermRef href="CDR0000045916" dictionary="Cancer.gov" audience="Patient">supplementation</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/>  Beta-blockers (drugs that slow the heart rate and lower
 <GlossaryTermRef href="CDR0000462668" dictionary="Cancer.gov" audience="Patient">blood pressure</GlossaryTermRef>) can inhibit coenzyme Q<Subscript>10</Subscript>-dependent enzyme
reactions.  The contractile force of the heart in patients with
 <GlossaryTermRef href="CDR0000458091" dictionary="Cancer.gov" audience="Patient">high blood pressure</GlossaryTermRef> can be increased by coenzyme Q<Subscript>10</Subscript>
administration.<Reference refidx="1"/>  Coenzyme Q<Subscript>10</Subscript> can reduce the body’s
response to the <GlossaryTermRef href="CDR0000046082" dictionary="Cancer.gov" audience="Patient">anticoagulant</GlossaryTermRef> drug 
<GlossaryTermRef href="CDR0000045249" dictionary="Cancer.gov" audience="Patient">warfarin</GlossaryTermRef>.<Reference refidx="10"/>  Finally,
coenzyme Q<Subscript>10</Subscript> can decrease <GlossaryTermRef href="CDR0000046187" dictionary="Cancer.gov" audience="Patient">insulin</GlossaryTermRef> requirements in individuals with
 <GlossaryTermRef href="CDR0000044911" dictionary="Cancer.gov" audience="Patient">diabetes</GlossaryTermRef>.</Para><ReferenceSection><Citation idx="1" PMID="10192685" MedlineID="99206903">Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999.</Citation><Citation idx="2" PMID="10556981" MedlineID="20025952">Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999.</Citation><Citation idx="3" PMID="10416054" MedlineID="99344543">Hodges S, Hertz N, Lockwood K, et al.: CoQ10: could it have a role in cancer management? Biofactors 9 (2-4): 365-70, 1999.</Citation><Citation idx="4" PMID="4689357" MedlineID="73130652">Heller JH: Disease, the host defense, and Q-10. Perspect Biol Med 16 (2): 181-7, 1973 Winter.</Citation><Citation idx="5" PMID="7752841" MedlineID="95272334">Baggio E, Gandini R, Plancher AC, et al.: Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 15 (Suppl): s287-94, 1994.</Citation><Citation idx="6" PMID="8723151" MedlineID="96300500">Feigin A, Kieburtz K, Como P, et al.: Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 11 (3): 321-3, 1996.</Citation><Citation idx="7" PMID="31855498">Ambrosone CB, Zirpoli GR, Hutson AD, et al.: Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol 38 (8): 804-814, 2020.</Citation><Citation idx="8" PMID="9989597" MedlineID="99142703">Kaikkonen J, Nyyssönen K, Tuomainen TP, et al.: Determinants of plasma coenzyme Q10 in humans. FEBS Lett 443 (2): 163-6, 1999.</Citation><Citation idx="9" PMID="9816194" MedlineID="99035042">Thibault A, Samid D, Tompkins AC, et al.: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2 (3): 483-91, 1996.</Citation><Citation idx="10">Coenzyme Q10. In: Jellin JM, Hitchens K, eds.: Natural Medicines Comprehensive Database. Therapeutic Research Faculty, 1999, pp 241-42.</Citation></ReferenceSection></SummarySection><SummarySection id="_30"><Title>Summary of the Evidence for Coenzyme Q<Subscript>10</Subscript></Title><Para id="_31">To assist readers in evaluating the results of human <GlossaryTermRef href="CDR0000044195" dictionary="Cancer.gov" audience="Patient">studies</GlossaryTermRef> of integrative, alternative, and complementary therapies for <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>, the strength of the evidence (i.e., the “<GlossaryTermRef href="CDR0000446533" dictionary="Cancer.gov" audience="Patient">levels of
evidence</GlossaryTermRef>”) associated with each type of treatment is provided whenever
possible.  To qualify for a level of evidence <GlossaryTermRef href="CDR0000390238" dictionary="Cancer.gov" audience="Patient">analysis</GlossaryTermRef>, a study must:</Para><ItemizedList id="_40" Style="bullet"><ListItem>Be published in a <GlossaryTermRef href="CDR0000537399" dictionary="Cancer.gov" audience="Patient">peer-reviewed scientific journal</GlossaryTermRef>.</ListItem><ListItem>Report on a <GlossaryTermRef href="CDR0000043985" dictionary="Cancer.gov" audience="Patient">therapeutic</GlossaryTermRef> <GlossaryTermRef href="CDR0000467853" dictionary="Cancer.gov" audience="Patient">outcome</GlossaryTermRef> or outcomes, such as <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">response</GlossaryTermRef>, improvement in survival, or measured improvement in <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</ListItem><ListItem>Describe clinical findings in sufficient detail that a meaningful evaluation can be made.</ListItem></ItemizedList><Para id="_41">Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes (i.e., <GlossaryTermRef href="CDR0000346519" dictionary="Cancer.gov" audience="Patient">endpoints</GlossaryTermRef>) measured. The resulting two scores are then combined to produce an overall score. A table showing the levels of evidence scores for qualifying human studies cited in this summary is presented below. For an explanation of the scores and additional information about levels of evidence analysis for cancer, see <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</SummaryRef>.</Para><Table id="_36"><Title>Coenzyme Q<Subscript>10</Subscript> Summary: Reference Numbers and the Corresponding Levels of Evidence</Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Reference
Number           </entry><entry>Statistical Strength of Study Design          </entry><entry>Strength of Endpoints
Measured          </entry><entry>Combined Score          </entry></Row></THead><TBody><Row><entry><Reference refidx="1"/></entry><entry>3iii ­ <GlossaryTermRef href="CDR0000044575" dictionary="Cancer.gov" audience="Patient">Nonconsecutive case series          </GlossaryTermRef></entry><entry>Diii ­ Indirect surrogates -- tumor response rate          </entry><entry><LOERef href="CDR0000335158" dictionary="NotSet" audience="Health professional">3iiiDiii</LOERef>          </entry></Row></TBody></TGroup></Table><ReferenceSection><Citation idx="1" PMID="7752835" MedlineID="95272328">Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994.</Citation></ReferenceSection></SummarySection><SummarySection id="_37"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (10/31/2024)</Title><Para id="_38">The <GlossaryTermRef href="CDR0000044271" dictionary="Cancer.gov" audience="Patient">PDQ</GlossaryTermRef> <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_94">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062979#_AboutThis_1" url="/about-cancer/treatment/cam/hp/coenzyme-q10-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of coenzyme Q10 in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Integrative, Alternative, and Complementary Therapies Editorial Board uses a <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Coenzyme Q10. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq">https://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389329]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2024-10-31</DateLastModified></Summary>
